- Home
- PRZO vs ONCO Comparison
PRZO vs ONCO Comparison
Compare PRZO & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- ONCO
- Stock Information
- Founded
- PRZO 2014
- ONCO 2018
- Country
- PRZO Israel
- ONCO United States
- Employees
- PRZO N/A
- ONCO N/A
- Industry
- PRZO
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- PRZO
- ONCO Health Care
- Exchange
- PRZO Nasdaq
- ONCO Nasdaq
- Market Cap
- PRZO 32.3M
- ONCO 4.7M
- IPO Year
- PRZO 2023
- ONCO 2022
- Fundamental
- Price
- PRZO $1.53
- ONCO $3.38
- Analyst Decision
- PRZO
- ONCO
- Analyst Count
- PRZO 0
- ONCO 0
- Target Price
- PRZO N/A
- ONCO N/A
- AVG Volume (30 Days)
- PRZO 989.7K
- ONCO 286.1K
- Earning Date
- PRZO 08-28-2025
- ONCO 08-14-2025
- Dividend Yield
- PRZO N/A
- ONCO N/A
- EPS Growth
- PRZO N/A
- ONCO N/A
- EPS
- PRZO N/A
- ONCO N/A
- Revenue
- PRZO $1,007,440.00
- ONCO $1,326,959.00
- Revenue This Year
- PRZO N/A
- ONCO N/A
- Revenue Next Year
- PRZO N/A
- ONCO N/A
- P/E Ratio
- PRZO N/A
- ONCO N/A
- Revenue Growth
- PRZO 80.42
- ONCO N/A
- 52 Week Low
- PRZO $0.53
- ONCO $2.45
- 52 Week High
- PRZO $3.16
- ONCO $552.50
- Technical
- Relative Strength Index (RSI)
- PRZO 45.31
- ONCO 51.12
- Support Level
- PRZO $1.63
- ONCO $3.51
- Resistance Level
- PRZO $1.80
- ONCO $4.17
- Average True Range (ATR)
- PRZO 0.11
- ONCO 0.28
- MACD
- PRZO -0.02
- ONCO 0.00
- Stochastic Oscillator
- PRZO 3.63
- ONCO 35.51
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.